FITC Annexin V 凋亡试剂盒 货号:640905

FITC Annexin V 凋亡试剂盒 货号:640905

FITC Annexin V 凋亡试剂盒

货  号:640905

产品规格:25T

原  产  地:USA

参考价格:910 (参考价格,以实际价格为准)

优惠价格:773

产品详细信息

FITC Annexin V 凋亡试剂盒 640905  25T

Reactivity:     All mammalian species
Formulation:     Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).
Preparation:     The purified protein was conjugated with FITC under optimal conditions. The solution is free of unconjugated FITC.
Storage & Handling:     The Annexin V solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application:     

FC – Quality tested
Recommended Usage:     

Each lot of this product is quality control tested by staining of apoptotic cells and analyzing by flow cytometry. The suggested use of this reagent is 5 µl per 1X105 cells in a 100 µl volume of Annexin V Binding Buffer (cat. no. 422201). It is recommended that the reagent be titrated for optimal performance for each application.
Excitation
Laser:     Blue Laser (488 nm)
Application
Notes:     

Annexin V Staining
1. Wash cells twice with cold BioLegend cell staining buffer (cat # 420201) and then resuspend cells in Annexin V Binding Buffer (cat # 422201) at a concentration of 1x10e6 cells/ml.
2. Transfer 100 µl of cell suspension in 5 ml test tube.
3. Add 5 µl of FITC Annexin V.
4. Add 10 µl of PI solution (cat # 421301) or 7-AAD (cat # 420403/420404).
5. Gently vortex the cells and incubate for 15 min at RT (25 °C) in the dark.
6. Add 400 µl of Annexin V Binding Buffer (cat # 422201) to each tube. Analyze by flow cytometry.
Application
References:     

1. Koopman G, et al. 1994. Blood 84:1415.
2. Vermes I, et al. 1995. J. Immunol. Methods 184:39.
3. Dachary-Prigent J, et al. 1993. Blood 81:2554.
4. Sekine C, et al. 2009. Int Immunol. PubMed
5. Grujic M, et al. 2010. J. Immunol. 185:1730. PubMed
6. Mulik RS, et al. 2010. Int J Pharm. 398:190. PubMed
7. Gupta A, et al. 2011. Leuk Res. 35:1498. PubMed
8. Speth C,et al. 2013. J Infect Dis. 207:823.  PubMed
9. Wang Q, et al. 2013. Genes Dev. 27:615. PubMed
10. Gill K, et al. 2013. Biocheim Biophys Acta. 830:2763. PubMed
11. Juel HB, et al. 2013. PLoS One. 8:64619. PubMed
12. Hellmann J, et al. 2013. J. Immunol. 191:1383. PubMed

产品详细信息

FITC Annexin V 凋亡试剂盒 640905  25T

Reactivity:     All mammalian species
Formulation:     Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).
Preparation:     The purified protein was conjugated with FITC under optimal conditions. The solution is free of unconjugated FITC.
Storage & Handling:     The Annexin V solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application:     

FC – Quality tested
Recommended Usage:     

Each lot of this product is quality control tested by staining of apoptotic cells and analyzing by flow cytometry. The suggested use of this reagent is 5 µl per 1X105 cells in a 100 µl volume of Annexin V Binding Buffer (cat. no. 422201). It is recommended that the reagent be titrated for optimal performance for each application.
Excitation
Laser:     Blue Laser (488 nm)
Application
Notes:     

Annexin V Staining
1. Wash cells twice with cold BioLegend cell staining buffer (cat # 420201) and then resuspend cells in Annexin V Binding Buffer (cat # 422201) at a concentration of 1x10e6 cells/ml.
2. Transfer 100 µl of cell suspension in 5 ml test tube.
3. Add 5 µl of FITC Annexin V.
4. Add 10 µl of PI solution (cat # 421301) or 7-AAD (cat # 420403/420404).
5. Gently vortex the cells and incubate for 15 min at RT (25 °C) in the dark.
6. Add 400 µl of Annexin V Binding Buffer (cat # 422201) to each tube. Analyze by flow cytometry.
Application
References:     

1. Koopman G, et al. 1994. Blood 84:1415.
2. Vermes I, et al. 1995. J. Immunol. Methods 184:39.
3. Dachary-Prigent J, et al. 1993. Blood 81:2554.
4. Sekine C, et al. 2009. Int Immunol. PubMed
5. Grujic M, et al. 2010. J. Immunol. 185:1730. PubMed
6. Mulik RS, et al. 2010. Int J Pharm. 398:190. PubMed
7. Gupta A, et al. 2011. Leuk Res. 35:1498. PubMed
8. Speth C,et al. 2013. J Infect Dis. 207:823.  PubMed
9. Wang Q, et al. 2013. Genes Dev. 27:615. PubMed
10. Gill K, et al. 2013. Biocheim Biophys Acta. 830:2763. PubMed
11. Juel HB, et al. 2013. PLoS One. 8:64619. PubMed
12. Hellmann J, et al. 2013. J. Immunol. 191:1383. PubMed